Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.

Abstract

The aim of the study was to test the hypothesis that B-cell repopulation following rituximab (anti-CD20) therapy is orchestrated by chemokines and non-chemokine cytokines. Twenty-five children with opsoclonus-myoclonus syndrome (OMS) received rituximab with or without conventional agents. A comprehensive panel of 40 chemokines and other cytokines were measured in serum by ELISA and multiplexed fluorescent bead-based immunoassay. Serum BAFF concentration changed dramatically (even after first infusion) and inversely with B-cell depletion/repopulation and CXCL13 concentration at 1, 3, and 6 months. Negative correlations were found for BAFF concentration vs blood B cell percentage and serum CXCL13 concentration; positive correlations with serum rituximab concentrations. Six months after initiation of therapy, no significant difference in the levels of APRIL, CXCL10, IL-6, or 17 other cytokines/chemokines were detected. These data reveal a major role for BAFF in peripheral B cell repopulation following rituximab-induced B-cell depletion, and novel changes in CXCL13. ClinicalTrials.gov NCT0024436.

• Authors: Michael R Pranzatelli, Elizabeth D Tate, Anna L Travelstead, Steven J Verhulst
• Journal: Cytokine (Cytokine) Vol. 53 Issue 3 Pg. 384-9 (Mar 2011) ISSN: 1096-0023 [Electronic] England
• PMID: 21211990 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• B-Cell Activating Factor
• CXCL13 protein, human
• Chemokine CXCL13
• Chemokines
• Cytokines
• Immunoglobulins, Intravenous
• Immunologic Factors
• TNFSF13B protein, human
• Rituximab
• Adrenocorticotropic Hormone

Topics

• Adrenocorticotropic Hormone (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Murine-Derived (administration & dosage, blood, therapeutic use)
• B-Cell Activating Factor (blood)
• B-Lymphocytes (drug effects, pathology)
• Chemokine CXCL13 (blood)
• Chemokines (blood)
• Child
• Cytokines (blood)
• Drug Administration Schedule
• Drug Therapy, Combination
• Enzyme-Linked Immunosorbent Assay
• Humans
• Immunoassay (methods)
• Immunoglobulins, Intravenous (administration & dosage, therapeutic use)
• Immunologic Factors (administration & dosage, blood, therapeutic use)
• Opsoclonus-Myoclonus Syndrome (blood, drug therapy)
• Rituximab
• Time Factors
• Treatment Outcome